[Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression]

Matthieu Roulleaux Dugage; Solenn Brosseau

doi:10.1016/j.bulcan.2021.06.011

[Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression]

Bull Cancer. 2021 Oct;108(10):904-906. doi: 10.1016/j.bulcan.2021.06.011. Epub 2021 Sep 29.

[Article in French]

Authors

Matthieu Roulleaux Dugage¹, Solenn Brosseau²

Affiliations

¹ Gustave Roussy, université Paris Saclay, département d'oncologie médicale, 94805 Villejuif, France. Electronic address: matthieu.roulleaux-dugage@gustaveroussy.fr.
² Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Bichat-Claude Bernard, département d'oncologie thoracique, 75018 Paris, France.

PMID: 34598788
DOI: 10.1016/j.bulcan.2021.06.011

No abstract available

Keywords: Atezolizumab; Cancer du poumon non à petites cellules (CBNPC); Immune checkpoint inhibitor; Immunotherapy; Immunothérapie; Inhibiteur de point de contrôle; Non-small-cell lung cancer (NSCLC); PD-L1.

Publication types

News

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
B7-H1 Antigen / metabolism*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
B7-H1 Antigen
CD274 protein, human
Immune Checkpoint Inhibitors
atezolizumab
pembrolizumab